• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

    8/5/25 4:01:19 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DERM alert in real time by email

    SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2025 financial results after the U.S. financial markets close on Tuesday, August 12, 2025. Journey Medical management will conduct a conference call and audio webcast on Tuesday, August 12, 2025 at 4:30 p.m. ET.

    To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10201702/ffa49f90a2. Please note that registered participants will receive their dial-in number upon registration.

    A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical's website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.

    About Journey Medical Corporation

    Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical") is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight FDA-approved prescription drugs for dermatological conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology's most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (NASDAQ:FBIO). Journey Medical's common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission ("SEC"). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

    Company Contact:

    Jaclyn Jaffe

    Journey Medical Corporation

    (781) 652-4500

    [email protected]

    Media Relations Contact:

    Tony Plohoros

    6 Degrees

    (908) 591-2839

    [email protected]  



    Primary Logo

    Get the next $DERM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DERM
    $FBIO

    CompanyDatePrice TargetRatingAnalyst
    Journey Medical Corporation
    $DERM
    8/25/2025$13.00Buy
    H.C. Wainwright
    Journey Medical Corporation
    $DERM
    7/30/2025$12.00Buy
    B. Riley Securities
    Journey Medical Corporation
    $DERM
    8/22/2024$9.00Buy
    Rodman & Renshaw
    Journey Medical Corporation
    $DERM
    6/28/2024$11.00Buy
    ROTH MKM
    Fortress Biotech Inc.
    $FBIO
    3/15/2024$10.00Buy
    ROTH MKM
    Fortress Biotech Inc.
    $FBIO
    8/4/2022$6.00Buy
    Ladenburg Thalmann
    Journey Medical Corporation
    $DERM
    2/25/2022$9.00Overweight
    Cantor Fitzgerald
    Journey Medical Corporation
    $DERM
    12/16/2021$15.00Buy
    Roth Capital
    More analyst ratings

    $DERM
    $FBIO
    SEC Filings

    View All

    Fortress Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Fortress Biotech, Inc. (0001429260) (Filer)

    10/1/25 8:45:20 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Journey Medical Corp (0001867066) (Filer)

    9/26/25 4:39:02 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Journey Medical Corp (0001867066) (Filer)

    8/28/25 5:30:07 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DERM
    $FBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

    Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% royalty on future net sales of dotinurad MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics, Inc. ("Crystalys"), in which Urica maintains an equity position, closed a $205 million Series A financing to support the advancement of global Phase 3 clinical studies evaluating dotinurad for the treatment of gout. The financing rou

    10/1/25 8:05:56 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter ("CRL") relating to the New Drug Application ("NDA") for CUTX-101 (copper histidinate), intended to treat Menkes disease in pediatric patients. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group") assumed full responsibility for the development and commercialization of CUTX-101 from Cyprium. Cyprium expects its partner, Sen

    10/1/25 8:00:46 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation to Participate in September 2025 Investor Conferences

    SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2025 investor conferences. Details of the events are as follows: H.C. Wainwright 27th Annual Global Investment Conference Date and Time: Monday, September 8, 2025, at 1:30 p.m. ETLocation: New York CityFormat: Fireside

    9/3/25 8:30:57 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DERM
    $FBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT, CEO & CHAIRMAN Rosenwald Lindsay A Md bought $1,404,581 worth of shares (763,359 units at $1.84), increasing direct ownership by 26% to 3,657,264 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    9/25/24 4:45:04 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO & Chairman Rosenwald Lindsay A Md bought $37,418 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (5,000 units at $7.48), increasing direct ownership by 4% to 127,500 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    7/15/24 4:05:14 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Jin David bought $3,750 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (500 units at $7.50) (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    7/12/24 8:42:21 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DERM
    $FBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Journey Medical with a new price target

    H.C. Wainwright initiated coverage of Journey Medical with a rating of Buy and set a new price target of $13.00

    8/25/25 8:12:40 AM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities resumed coverage on Journey Medical with a new price target

    B. Riley Securities resumed coverage of Journey Medical with a rating of Buy and set a new price target of $12.00

    7/30/25 8:21:38 AM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Journey Medical with a new price target

    Rodman & Renshaw initiated coverage of Journey Medical with a rating of Buy and set a new price target of $9.00

    8/22/24 7:21:37 AM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DERM
    $FBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Maraoui Claude exercised 1,250,000 shares at a strike of $0.07 and covered exercise/tax liability with 10,877 shares, increasing direct ownership by 108% to 2,386,713 units (SEC Form 4)

    4 - Journey Medical Corp (0001867066) (Issuer)

    8/26/25 9:54:28 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Rosenwald Lindsay A Md was granted 50,000 shares, increasing direct ownership by 31% to 211,146 units (SEC Form 4)

    4 - Journey Medical Corp (0001867066) (Issuer)

    8/7/25 5:18:06 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Justin Adam was granted 20,000 shares, increasing direct ownership by 13% to 171,618 units (SEC Form 4)

    4 - Journey Medical Corp (0001867066) (Issuer)

    8/7/25 5:17:19 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DERM
    $FBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Journey Medical to Join Russell 2000® and Russell 3000® Indexes

    SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

    6/24/25 8:30:29 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

    SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

    4/1/25 4:01:16 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

    SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves

    7/11/24 4:05:39 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DERM
    $FBIO
    Financials

    Live finance-specific insights

    View All

    Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

    Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% royalty on future net sales of dotinurad MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics, Inc. ("Crystalys"), in which Urica maintains an equity position, closed a $205 million Series A financing to support the advancement of global Phase 3 clinical studies evaluating dotinurad for the treatment of gout. The financing rou

    10/1/25 8:05:56 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter ("CRL") relating to the New Drug Application ("NDA") for CUTX-101 (copper histidinate), intended to treat Menkes disease in pediatric patients. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group") assumed full responsibility for the development and commercialization of CUTX-101 from Cyprium. Cyprium expects its partner, Sen

    10/1/25 8:00:46 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

    Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl) FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults MIAMI, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing a

    8/14/25 4:05:03 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DERM
    $FBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Fortress Biotech Inc.

    SC 13G - Fortress Biotech, Inc. (0001429260) (Subject)

    10/25/24 10:15:19 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Fortress Biotech Inc.

    SC 13D/A - Fortress Biotech, Inc. (0001429260) (Subject)

    9/25/24 4:45:18 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care